About One cut domain family member 3
One cut domain family member 3 (ONECUT3) is a protein
from Homo sapiens identified by UniProt accession
O60422, 494 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | One cut domain family member 3 |
| UniProt accession | O60422 |
| Gene | ONECUT3 |
| Organism | Homo sapiens |
| Length | 494 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (26)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- visual perception measurement · score 0.28
- myelodysplastic syndrome · score 0.07
- Barrett's esophagus · score 0.06
- esophageal adenocarcinoma · score 0.04
- mean corpuscular volume · score 0.02
- cancer · score 0.02
- neoplasm · score 0.01
- colorectal adenocarcinoma · score 0.01
- non-small cell lung carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60422-F1 | alphafold | PREDICTED | 56.85 | — |
Amino-acid sequence (494 residues)
MELSLESLGG LHSVAHAQAG ELLSPGHARS AAAQHRGLVA PGRPGLVAGM ASLLDGGGGG GGGGAGGAGG AGSAGGGADF RGELAGPLHP AMGMACEAPG LGGTYTTLTP LQHLPPLAAV ADKFHQHAAA AAVAGAHGGH PHAHPHPAAA PPPPPPPQRL AASVSGSFTL MRDERAALAS VGHLYGPYGK ELPAMGSPLS PLPNALPPAL HGAPQPPPPP PPPPLAAYGP PGHLAGDKLL PPAAFEPHAA LLGRAEDALA RGLPGGGGGT GSGGAGSGSA AGLLAPLGGL AAAGAHGPHG GGGGPGGSGG GPSAGAAAEE INTKEVAQRI TAELKRYSIP QAIFAQRILC RSQGTLSDLL RNPKPWSKLK SGRETFRRMW KWLQEPEFQR MSALRLAACK RKEQEQQKER ALQPKKQRLV FTDLQRRTLI AIFKENKRPS KEMQVTISQQ LGLELNTVSN FFMNARRRCM NRWAEEPSTA PGGPAGATAT FSKA
Explore One cut domain family member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets